Capricor Therapeutics, Inc. (CAPR): Shareholders' Equity
$305.79M
As of 2025-12-31
$246.22M
As of 2026-06-30
+196.0%
3-year compound annual growth
+61.1%
5-year compound annual growth
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $305.79M | +110.2% | 2026-03-17, Balance as of period end |
| 2024-12-31 | $145.46M | +543.6% | 2026-03-17, Balance as of period end |
| 2023-12-31 | $22.60M | +91.8% | 2025-03-26, Balance as of period end |
| 2022-12-31 | $11.79M | -62.4% | 2024-03-11, Balance as of period end |
| 2021-12-31 | $31.37M | +11.2% | 2023-03-17, Balance as of period end |
| 2020-12-31 | $28.20M | +312.3% | 2022-03-11, Balance as of period end |
| 2019-12-31 | $6.84M | +48.2% | 2021-03-15, Balance as of period end |
| 2018-12-31 | $4.62M | -58.9% | 2020-03-27, Balance as of period end |
| 2017-12-31 | $11.23M | n/m | 2019-03-29, Balance as of period end |
| 2016-12-31 | -$4.00M | n/m | 2018-03-22, Balance as of period end |
| 2015-12-31 | -$1.03M | n/m | 2017-03-16, Balance as of period end |
| 2014-12-31 | -$6.25M | n/m | 2016-03-30, Balance as of period end |
| 2013-12-31 | -$534.9K | n/m | 2015-03-16, Balance as of period end |
| 2012-12-31 | $4.89M | +195.7% | 2014-03-31, Balance as of period end |
| 2011-12-31 | $1.66M | -7.5% | 2014-03-31, Balance as of period end |
| 2010-12-31 | $1.79M | +96.2% | 2014-03-31, Balance as of period end |
| 2009-12-31 | $911.8K | +261.0% | 2014-03-31, Balance as of period end |
| 2008-12-31 | $252.6K | -70.7% | 2014-03-31, Balance as of period end |
| 2007-12-31 | $863.2K | -53.0% | 2014-03-31, Balance as of period end |
| 2006-12-31 | $1.84M | n/a | 2014-03-31, Balance as of period end |
| 2005-12-31 | $0 | n/a | 2014-03-31, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| Capricor Therapeutics, Inc. (CAPR) | 2025-12-31 | $305.79M | +110.2% |
| Abbott Laboratories (ABT) | 2025-12-31 | $52.13B | +9.4% |
| Bristol Myers Squibb Co (BMY) | 2025-12-31 | $18.47B | +13.1% |
| TherapeuticsMD, Inc. (TXMD) | 2025-12-31 | $26.88M | -1.8% |
| Eli Lilly & Co (LLY) | 2025-12-31 | $26.54B | +85.9% |
| Pfizer Inc (PFE) | 2025-12-31 | $86.78B | -1.9% |
| Johnson & Johnson (JNJ) | 2025-12-28 | $81.54B | +14.1% |
| Nature's Sunshine Products Inc (NATR) | 2025-12-31 | $161.55M | +0.3% |
| Merck & Co., Inc. (MRK) | 2025-12-31 | $52.66B | +13.6% |
Compare CAPR, ABT, BMY, TXMD side by side · Screen every company in Pharmaceutical Preparations ↗